ARS Pharmaceuticals, Inc Capital Reinvestment Ratio
ARS Pharmaceuticals, Inc capital reinvestment ratio. ARS Pharmaceuticals, Inc (SPRY) has a Capital Reinvestment Ratio of 0.01x as of December 2024, meaning it reinvests 0% of its operating cash flow ($42.00 Million) in capital expenditures ($302.00K). Check ARS Pharmaceuticals, Inc (SPRY) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of ARS Pharmaceuticals, Inc (2020–2024)
Capital reinvestment ratio of ARS Pharmaceuticals, Inc from 2020 to 2024. This chart tracks ARS Pharmaceuticals, Inc's Capital Reinvestment Ratio across 2 annual periods. Also explore how fast is ARS Pharmaceuticals, Inc growing its equity to track the company's year-over-year net asset growth rate.
ARS Pharmaceuticals, Inc Capital Reinvestment Ratio by Year (2020–2024)
ARS Pharmaceuticals, Inc capital reinvestment ratio by year from 2020 to 2024. For the full cash flow conversion analysis, see SPRY operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.04x | $13.55 Million | $563.00K | ▼ -58.9% |
| 2020 | 0.10x | $9.07 Million | $917.00K | — |